INmune Bio Inc. announced positive results from its AD02 Phase II Alzheimer's trial, showing strong performance of a new cognitive measure and significant correlation with established clinical endpoints.
AI Assistant
INMUNE BIO INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.